Programmed Cell Death 4 ( PDCD 4 ) Enhances the Sensitivity of Gastric Cancer Cells to TRAIL-Induced Apoptosis by Inhibiting the PI 3 K / Akt Signaling Pathway

AbstractObjective: Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) is thought to be a promising anti-neoplastic agent because of its ability to selectively induce apoptosis in cancer cells. However, some cancer cells are resistant to TRAIL. The mechanisms underlying this resistance are unclear. The aim of this study was to explore the role of programmed cell death 4 (PDCD4) in regulating TRAIL sensitivity in gastric cancer cells. Methods: PDCD4 complementary DNA and PDCD4-specific short-hairpin RNA (shRNA) fragments were transfected into TRAIL-sensitive and -resistant gastric cancer cells. Expression of PDCD4 and Akt was detected via western blot. Cell survival and apoptosis were measured using 3-(4,5-dimethylthiazolyl)-2,5-diphenyltetrazolium bromide (MTT) and flow cytometry (FCM) assays. Results: We found that upregulation of PDCD4 enhanced TRAIL sensitivity in gastric cancer cells. Downregulation of PDCD4 decreased TRAIL sensitivity. Inhibition of Akt by the phosphoinositide 3-kinase (PI3K) inhibitor LY294002 induced PDCD4 activity and enhanced TRAIL sensitivity in TRAIL-resistant gastric cancer cells. Conclusion: We demonstrated that PDCD4 regulates TRAIL sensitivity in gastric cancer cells by inhibiting the PI3K/Akt signaling pathway.

[1]  R. Epstein,et al.  Upregulated Akt signaling adjacent to gastric cancers: implications for screening and chemoprevention. , 2005, Cancer letters.

[2]  C. Sawyers,et al.  The phosphatidylinositol 3-Kinase–AKT pathway in human cancer , 2002, Nature Reviews Cancer.

[3]  Myung-Haing Cho,et al.  Aerosol delivery of urocanic acid–modified chitosan/programmed cell death 4 complex regulated apoptosis, cell cycle, and angiogenesis in lungs of K-ras null mice , 2006, Molecular Cancer Therapeutics.

[4]  W. Cavenee,et al.  Increased death receptor 5 expression by chemotherapeutic agents in human gliomas causes synergistic cytotoxicity with tumor necrosis factor-related apoptosis-inducing ligand in vitro and in vivo. , 2000, Cancer research.

[5]  W. El-Deiry,et al.  Cell surface Death Receptor signaling in normal and cancer cells. , 2003, Seminars in cancer biology.

[6]  L. Xia,et al.  PI3 kinase/Akt signaling mediates epithelial-mesenchymal transition in hypoxic hepatocellular carcinoma cells. , 2009, Biochemical and biophysical research communications.

[7]  Birgit Samans,et al.  Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21Waf1/Cip1 , 2004 .

[8]  Michael T. Fisher,et al.  Molecular determinants of response to TRAIL in killing of normal and cancer cells. , 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

[9]  D. Dicker,et al.  Enhanced TRAIL sensitivity by p53 overexpression in human cancer but not normal cell lines. , 2001, International journal of oncology.

[10]  C. Rancourt,et al.  Malignant ascites protect against TRAIL‐induced apoptosis by activating the PI3K/Akt pathway in human ovarian carcinoma cells , 2007, International journal of cancer.

[11]  Lewis C Cantley,et al.  The phosphoinositide 3-kinase pathway. , 2002, Science.

[12]  Alfonso Bellacosa,et al.  AKT plays a central role in tumorigenesis , 2001, Proceedings of the National Academy of Sciences of the United States of America.

[13]  L. Platanias,et al.  Statin-Dependent Suppression of the Akt/Mammalian Target of Rapamycin Signaling Cascade and Programmed Cell Death 4 Up-Regulation in Renal Cell Carcinoma , 2008, Clinical Cancer Research.

[14]  Michele Pagano,et al.  S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth , 2006, Science.

[15]  L. Cantley,et al.  Targeting the PI3K-Akt pathway in human cancer: rationale and promise. , 2003, Cancer cell.

[16]  D. Lawrence,et al.  Safety and antitumor activity of recombinant soluble Apo2 ligand. , 1999, The Journal of clinical investigation.

[17]  R. K Srivastava,et al.  Constitutively active Akt is an important regulator of TRAIL sensitivity in prostate cancer , 2001, Oncogene.

[18]  Frank McCormick,et al.  Akt activation by growth factors is a multiple-step process: the role of the PH domain , 1998, Oncogene.

[19]  P. Tsichlis,et al.  AKT/PKB and other D3 phosphoinositide-regulated kinases: kinase activation by phosphoinositide-dependent phosphorylation. , 1999, Annual review of biochemistry.

[20]  R. K Srivastava,et al.  Pro-survival Function of Akt/Protein Kinase B in Prostate Cancer Cells , 2001, The Journal of Biological Chemistry.

[21]  L. Platanias,et al.  Suppression of Programmed Cell Death 4 (PDCD4) Protein Expression by BCR-ABL-regulated Engagement of the mTOR/p70 S6 Kinase Pathway* , 2008, Journal of Biological Chemistry.

[22]  M. Smyth,et al.  TRAIL and its receptors as targets for cancer therapy , 2004, Cancer science.

[23]  Tobias Schmid,et al.  Translation inhibitor Pdcd4 is targeted for degradation during tumor promotion. , 2008, Cancer research.

[24]  T L Chenevert,et al.  Combined effect of tumor necrosis factor-related apoptosis-inducing ligand and ionizing radiation in breast cancer therapy. , 2000, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Pieper,et al.  Translational Regulation of TRAIL Sensitivity , 2006, Cell cycle.

[26]  N. Colburn,et al.  Programmed Cell Death-4 Tumor Suppressor Protein Contributes to Retinoic Acid–Induced Terminal Granulocytic Differentiation of Human Myeloid Leukemia Cells , 2007, Molecular Cancer Research.

[27]  N. Colburn,et al.  Tumorigenesis Suppressor Pdcd4 Down-Regulates Mitogen-Activated Protein Kinase Kinase Kinase Kinase 1 Expression To Suppress Colon Carcinoma Cell Invasion , 2006, Molecular and Cellular Biology.

[28]  H. Allgayer,et al.  Loss of programmed cell death 4 expression marks adenoma‐carcinoma transition, correlates inversely with phosphorylated protein kinase B, and is an independent prognostic factor in resected colorectal cancer , 2007, Cancer.

[29]  N. Colburn,et al.  Differentially expressed protein Pdcd4 inhibits tumor promoter-induced neoplastic transformation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[30]  Chunhong Ma,et al.  Frequent loss of PDCD4 expression in human glioma: possible role in the tumorigenesis of glioma. , 2007, Oncology reports.

[31]  T. Gress,et al.  Knockdown of Pdcd4 results in induction of proprotein convertase 1/3 and potent secretion of chromogranin A and secretogranin II in a neuroendocrine cell line , 2008, Biology of the cell.

[32]  Y. Pekarsky,et al.  Akt phosphorylates and regulates Pdcd4 tumor suppressor protein. , 2005, Cancer research.

[33]  Michele Pagano,et al.  S6K1- and betaTRCP-mediated degradation of PDCD4 promotes protein translation and cell growth. , 2006, Science.

[34]  Jennifer L. Knies,et al.  Pdcd4 suppresses tumor phenotype in JB6 cells by inhibiting AP-1 transactivation , 2003, Oncogene.

[35]  T. Griffith,et al.  TRAIL: a molecule with multiple receptors and control mechanisms. , 1998, Current opinion in immunology.

[36]  E. Tokunaga,et al.  Akt phosphorylation associates with LOH of PTEN and leads to chemoresistance for gastric cancer , 2005, International journal of cancer.

[37]  F. Kruyt.  TRAIL and cancer therapy. , 2008, Cancer letters.

[38]  Y. Matsuda,et al.  Significance of Akt Phosphorylation on Tumor Growth and Vascular Endothelial Growth Factor Expression in Human Gastric Carcinoma , 2006, Pathobiology.

[39]  S. Chiou,et al.  2‐Methoxyestradiol attenuates phosphatidylinositol 3‐kinase/Akt pathway‐mediated metastasis of gastric cancer , 2007, International journal of cancer.

[40]  N. Colburn,et al.  Epidermal expression of the translation inhibitor programmed cell death 4 suppresses tumorigenesis. , 2005, Cancer research.

[41]  K. M. Nicholson,et al.  The protein kinase B/Akt signalling pathway in human malignancy. , 2002, Cellular signalling.

[42]  A. Hasilik,et al.  Pdcd4 inhibits growth of tumor cells by suppression of carbonic anhydrase type II , 2004, Molecular and Cellular Endocrinology.

[43]  B. Hilliard,et al.  Translational Regulation of Autoimmune Inflammation and Lymphoma Genesis by Programmed Cell Death 41 , 2006, The Journal of Immunology.

[44]  J. S. Lee,et al.  RNAi Codex: a portal/database for short-hairpin RNA (shRNA) gene-silencing constructs , 2005, Nucleic Acids Res..

[45]  Iver Petersen,et al.  Loss of PDCD4 expression in human lung cancer correlates with tumour progression and prognosis , 2003, The Journal of pathology.

[46]  H. Zhang,et al.  Involvement of programmed cell death 4 in transforming growth factor-β1-induced apoptosis in human hepatocellular carcinoma , 2006, Oncogene.

[47]  Ye Zhang,et al.  PI3K/Akt is involved in bufalin-induced apoptosis in gastric cancer cells , 2009, Anti-cancer drugs.

[48]  B. Samans,et al.  Programmed cell death protein 4 suppresses CDK1/cdc2 via induction of p21(Waf1/Cip1). , 2004, American journal of physiology. Cell physiology.

[49]  N. Colburn,et al.  A novel transformation suppressor, Pdcd4, inhibits AP-1 transactivation but not NF-κB or ODC transactivation , 2001, Oncogene.

[50]  N. Colburn,et al.  Characterization of programmed cell death 4 in multiple human cancers reveals a novel enhancer of drug sensitivity. , 2004, Molecular cancer therapeutics.